Get started
Author

Isaac Cebrecos

Observed names: I Cebrecos, I Cebrecos Lerena, I. Cebrecos, I.Cebrecos Lerena, Isaac Cebrecos Lerena
ORCID: 0000-0002-9333-3642
Observed ORCID: 0000-0002-9333-3642
OpenAlex ID: A5030540833
Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer
2012 · Isabel T. Rubio, Isaac Cebrecos, et al. · Journal of Surgical Oncology · 33
The prevalence of congenital varicella syndrome after a maternal infection, but before 20 weeks of pregnancy: a prospective cohort study
2010 · Maria Angeles Sanchez, Juan Carlos Bello-Munoz, et al. · The Journal of Maternal-Fetal & Neonatal Medicine · 33
Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study
2022 · E. Mension, I. Alonso, et al. · Climacteric · 29
Can we predict local recurrence in breast conserving surgery after neoadjuvant chemotherapy?
2010 · I. Cebrecos, O. Córdoba, et al. · European Journal of Surgical Oncology · 26
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-negative breast cancer: the NEOENDO translational study
2024 · Francesco Schettini, Fara Brasó-Maristany, et al. · ESMO Open · 20
PDF
Sexual Function in Breast Cancer Patients: A Review of the Literature
2022 · Helena Castillo, Eduard Mension, et al. · Clinical and Experimental Obstetrics & Gynecology · 19
PDF
Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies
2023 · C. Castelo-Branco, E. Mension, et al. · Climacteric · 17
PDF
Evolution of breast conserving surgery—current implementation of oncoplastic techniques in breast conserving surgery: a literature review
2024 · Inés Torras, Isaac Cebrecos, et al. · Gland Surgery · 12
Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
2022 · Francesco Schettini, Elia Seguí, et al. · Frontiers in Oncology · 10
PDF
Radioactive and non-radioactive seeds as surgical localization method of non-palpable breast lesions
2022 · I. Cebrecos, N. Sánchez-Izquierdo, et al. · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · 10
Elacestrant in Women with Estrogen Receptor–Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial
2025 · Maria Vidal, Claudette Falato, et al. · Clinical Cancer Research · 9
PDF
Genomic and clinical features in young women with estrogen receptor-positive, HER2-negative breast cancer
2025 · B. Walbaum, O. Martínez-Sáez, et al. · ESMO Open · 7
Analysis of Local Recurrence Risk in Ductal Carcinoma In Situ and External Validation of the Memorial Sloan Kettering Cancer Center Nomogram
2023 · Gabriela Oses, Eduard Mension, et al. · Cancers · 7
PDF
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study
2025 · Thorsten Kühn, Maggie Banys-Paluchowski, et al. · British journal of surgery · 6
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice
2025 · Miriam Potrony, Blai Morales-Romero, et al. · Breast Cancer Research and Treatment · 6
Paclitaxel-related type I Kounis Syndrome in a very young patient with HER2-positive breast cancer and the role of genomics to disentangle a complex therapeutic scenario: a case report and narrative review
2025 · Javier Muñoz, Sabrina Nucera, et al. · The Breast · 5
Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal
2023 · Isaac Cebrecos, Eduard Mension, et al. · Annals of Surgical Oncology · 5
PDF
132TiP HCB-ONC001 ELPIS TRIAL: Omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard anti-HER2-based neoadjuvant therapy
2022 · T. Pascual, N. Chic, et al. · Annals of Oncology · 4
PDF
Aquaporin-4-Positive Triple-Negative Breast Cancer Presenting with Paraneoplastic Neuromyelitis Optica Spectrum Disorder
2022 · Pilar Carrillo, Teresa Gorría, et al. · Biomedicine Hub · 4
Preoperative Radiation Therapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results From the YOUNGSTER trial
2025 · Carles Gomà, Meritxell Mollà, et al. · International Journal of Radiation Oncology*Biology*Physics · 3
PDF
Predicting Additional Metastases in Axillary Lymph Node Dissection After Neoadjuvant Chemotherapy: Ratio of Positive/Total Sentinel Nodes
2024 · Isaac Cebrecos, Ines Torras, et al. · Cancers · 3
PDF
275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)
2023 · F. Schettini, F. Brasó-Maristany, et al. · Annals of Oncology · 3
PDF
55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)
2023 · F. Schettini, T. Pascual, et al. · ESMO Open · 3
PDF
ASO Visual Abstract: Nonsentinel Axillary Lymph-Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph-Node—A Predictive Model Proposal
2023 · Isaac Cebrecos, Eduard Mension, et al. · Annals of Surgical Oncology · 2
Surgical Management and Its Impact on Adjuvant Treatment in Recurrent Ipsilateral Breast Cancer: A Retrospective Cohort Study
2024 · Ines Torras, Isaac Cebrecos, et al. · Journal of Clinical Medicine · 1
PDF
Works count: 52
Citation count: 280
H-index: 10
I10-index: 10
Year
Topic
Type